Daban Claire, Martinez-Aran Anabel, Cruz Nuria, Vieta Eduard
Bipolar Disorders Program, Hospital Clinic, University of Barcelona, IDIBAPS, CIBER-SAM, Barcelona, Spain.
J Affect Disord. 2008 Sep;110(1-2):1-15. doi: 10.1016/j.jad.2008.02.012. Epub 2008 Mar 28.
OBJECTIVE: The main objective of this review of the literature was to evaluate the safety and efficacy of Vagus Nerve Stimulation (VNS) in treatment-resistant depression (TRD) by means of systematic review and meta-analysis. METHODS: A systematic review of the literature was made using the major databases (Medline, Psychological Abstracts, Current Contents), beginning in January 2000 and ending in September 2007. Ninety-eight references were found, but only 18 add-on studies met the required quality criteria and were included in this review. Only one double-blind, randomized study was available and therefore a meta-analysis was not feasible. RESULTS: In a majority of the preliminary open studies selected for this review, VNS was associated with a significant reduction of the depressive symptoms (primary outcome: Hamilton Depression Rating Scale, HDRS) in the short and long term. Unfortunately, the only double-blind study gave rather inconclusive results. Generally, VNS is reported to be a safe and feasible procedure, despite its invasive nature. CONCLUSIONS: VNS seems to be an interesting new approach to treating TRD. However, despite the promising results reported mainly in open studies, further clinical trials are needed to confirm its efficacy in major depression. Moreover, studies on its mechanism of action and cost-effectiveness are also required to better understand and develop VNS therapy for affective disorder.
目的:本文献综述的主要目的是通过系统评价和荟萃分析,评估迷走神经刺激(VNS)治疗难治性抑郁症(TRD)的安全性和有效性。 方法:利用主要数据库(Medline、心理学文摘、现刊目次)对文献进行系统综述,检索时间从2000年1月至2007年9月。共找到98篇参考文献,但只有18项附加研究符合所需质量标准并纳入本综述。仅有一项双盲随机研究,因此无法进行荟萃分析。 结果:在本次综述所选的大多数初步开放性研究中,VNS在短期和长期均与抑郁症状显著减轻相关(主要结局:汉密尔顿抑郁量表,HDRS)。遗憾的是,唯一的双盲研究结果相当不确定。总体而言,尽管VNS具有侵入性,但据报道它是一种安全可行的治疗方法。 结论:VNS似乎是治疗TRD的一种有趣的新方法。然而,尽管主要在开放性研究中报告了有前景的结果,但仍需要进一步的临床试验来证实其在重度抑郁症中的疗效。此外,还需要对其作用机制和成本效益进行研究,以更好地理解和开发用于情感障碍的VNS疗法。
Cochrane Database Syst Rev. 2022-7-14
Cochrane Database Syst Rev. 2018-5-14
Health Technol Assess. 2024-10
Cochrane Database Syst Rev. 2021-4-19
Health Technol Assess. 2001
Cochrane Database Syst Rev. 2004
Cochrane Database Syst Rev. 2017-12-22
Biomedicines. 2024-2-9
Front Pharmacol. 2023-10-2
Semin Cell Dev Biol. 2024-3-15
Front Neurol. 2022-11-10